Advice

in the absence of a submission from the holder of the marketing authorisation:

cobimetinib (Cotellic®) is not recommended for use within NHS Scotland.

Indication under review: in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
cobimetinib (Cotellic)
SMC ID:
1191/16
Indication:
In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
12 September 2016